Synergistic effect between two bacteriocin-like inhibitory substances produced by Lactobacilli Strains with inhibitory activity for Streptococcus agalactiae.
Group B streptococci (GBS) are bacterial species that colonize the vagina in pregnant women and as such may cause serious infections in neonates that passed through the birth channel. The objective of this work was to study the inhibitory activities produced by each bacteriocin-like inhibitory substance (BLIS) of Lactobacillus rhamnosus L60 and Lactobacillus fermentum L23, and the effects of the combined BLIS-es of these lactobacilli on GBS. The interactions between the BLIS-es were assessed by qualitative and quantitative methods on agar plates. The minimum inhibitory concentrations (MICs) and fractional inhibitory concentrations (FICs) were determined by a modification of the broth microdilution and checkerboard methods, respectively. Antibiotic susceptibilities of all S. agalactiae strains were assayed and the results of these tests were evaluated for statistical significance. A 7.5% of GBS isolates were recovered from 760 pregnant women and 91% of those strains were susceptible to each BLIS produced by L. fermentum, L. rhamnosus, and also to a mixture of them. The comparisons among the BLIS-es showed statistically significant differences, with a combination of the BLIS-es from the two Lactobacillus species being better than the BLIS of each one alone (P < 0.05) as GBS growth inhibitors. Synergistic activities between the BLIS-es were found on 100% of susceptible GBS strains, MICs ranges of BLIS of L23 and L60 were 80-160 and 160-320 UA ml(-1), respectively. By the checkerboard method, the BLIS-es combination showed synergistic effect on all sensitive strains tested, with values of FICs ranging from 0.131 to 0.218. The BLIS-es produced by these lactobacilli of vaginal origin were able to inhibit S. agalactiae isolates. The results indicate that these strains may have probiotic potential for the control of GBS in women and may consequently prevent GBS infections in newborns.
Departamento Microbiología e Inmunología, Universidad Nacional de Río Cuarto, 5800 Río Cuarto, Córdoba, Argentina. fruiz@exa.unrc.edu.ar
Francisco O
FO
Ruíz
Gisela
G
Gerbaldo
María J
MJ
García
Walter
W
Giordano
Liliana
L
Pascual
Isabel L
IL
Barberis
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001430:Bacteriocins / Q000378:metabolism / Q000494:pharmacology*; D016000:Cluster Analysis; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D004357:Drug Synergism; D005260:Female; D006801:Humans; D052197:Limosilactobacillus fermentum / Q000145:classification / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D052201:Lacticaseibacillus rhamnosus / Q000145:classification / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010802:Phylogeny; D011247:Pregnancy; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D017422:Sequence Analysis, DNA; D013290:Streptococcal Infections / Q000382:microbiology; D013292:Streptococcus agalactiae / Q000187:drug effects* / Q000254:growth & development* / Q000302:isolation & purification; D014621:Vagina / Q000382:microbiology
D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S